Usefulness of PIVKA-II for diagnosis and evaluation of recurrence of hepatocellular carcinoma.
- Author:
Do Young KIM
1
;
Yong Han PAIK
;
Kwang Hyub HAN
;
Sang Hoon AHN
;
Kyung Kyu KIM
;
Ja Kyung KIM
;
Myoung Ki SIM
;
Kwan Sik LEE
;
Chae Yoon CHON
;
Young Myoung MOON
Author Information
1. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. gihankhys@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
PIVKA-II;
Carcinoma;
Hepatocellular
- MeSH:
alpha-Fetoproteins;
Carcinoma, Hepatocellular*;
Diagnosis*;
Humans;
Liver Diseases;
Recurrence*;
Sensitivity and Specificity;
Vitamin K
- From:Korean Journal of Medicine
2005;69(1):39-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Although alpha-fetoprotein (AFP) is most widely used tumor marker for hepatocellular carcinoma (HCC), the sensitivity is about 60~70% in advanced HCC. Furthermore, the specificity of AFP is relatively low. The aim of this study was to evaluate the usefulness of prothrombin-induced by vitamin K absence or antagonist-II (PIVKA-II) in diagnosis of HCC, and of recurrence after curative surgical resection. METHODS: Between April 2001 and March 2004, a total of 245 patients with pathologically confirmed HCC and a total of 267 patients with non-HCC, chronic liver diseases were enrolled. RESULTS: With cutoff-value 20 ng/mL for AFP and 40 mAU/mL for PIVKA-II, the sensitivity of AFP and PIVKA-II was 48.6% (119/245) and 75.1% (184/245), respectively. The specificity of them was 81.3% (217/267) and 94.8% (253/267), respectively. When AFP and PIVKA-II were combined, the sensitivity and specificity was 83.3% (204/245) and 77.2% (206/267), respectively. For HCC
